AD diagnosis and staging rely on cognitive, functional, and behavioral tests, cerebrospinal fluid (CSF) and plasma analyses of amyloid β (Aβ) protein and hyperphosphorylated tau (ptau), as well as brain imaging analyses of amyloid and tau. The gene discussed is MAPT; the disease is Alzheimer disease.